A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
Study MO39874 is an open-label, Phase IIIb, single arm, global study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received chemotherapy for their unresectable locally advanced or metastatic disease.
Triple-Negative Breast Cancer
DRUG: Atezolizumab|DRUG: Nab-Paclitaxel
Percentage of Participants with treatment-emergent Grade≥3 AEs, From baseline to up to 4.5 years|Percentage of Participants with treatment-emergent Grade≥2 imAEs, From baseline to up to 4.5 years
Percentage of Participants with all treatment-emergent AEs, From baseline to up to 4.5 years|Percentage of Participants with treatment-emergent SAEs, From baseline to up to 4.5 years|Overall survival (OS) in ITT Population, OS defined as the time from initiation of study treatment to death from any cause., From baseline to 4.5 years|Overall survival (OS) in PD-L1-Positive Tumor Status Population, OS defined as the time from initiation of study treatment to death from any cause., From baseline to 4.5 years|Progression Free Survival (PFS) in ITT Population, PFS defined as the time from initiation of study treatment to the first occurrence of disease progression or death from any cause, whichever occurs first. PFS will be assessed by the investigator according to RECIST v1.1., From baseline to 4.5 years|Progression Free Survival (PFS) in PD-L1-Positive Tumor Status Population, PFS defined as the time from initiation of study treatment to the first occurrence of disease progression or death from any cause, whichever occurs first. PFS will be assessed by the investigator according to RECIST v1.1., From baseline to 4.5 years
Study MO39874 is an open-label, Phase IIIb, single arm, global study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received chemotherapy for their unresectable locally advanced or metastatic disease.